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Background: A rigorous and focused systematic review and meta-analysis of randomised controlled trials (RCTs) of
individualised homeopathic treatment has not previously been undertaken. We tested the hypothesis that the
outcome of an individualised homeopathic treatment approach using homeopathic medicines is distinguishable
from that of placebos.
Methods: The review’s methods, including literature search strategy, data extraction, assessment of risk of bias and
statistical analysis, were strictly protocol-based. Judgment in seven assessment domains enabled a trial’s risk of bias
to be designated as low, unclear or high. A trial was judged to comprise ‘reliable evidence’ if its risk of bias was low
or was unclear in one specified domain. ‘Effect size’ was reported as odds ratio (OR), with arithmetic transformation
for continuous data carried out as required; OR > 1 signified an effect favouring homeopathy.
Results: Thirty-two eligible RCTs studied 24 different medical conditions in total. Twelve trials were classed ‘uncertain
risk of bias’, three of which displayed relatively minor uncertainty and were designated reliable evidence; 20 trials
were classed ‘high risk of bias’. Twenty-two trials had extractable data and were subjected to meta-analysis; OR = 1.53
(95% confidence interval (CI) 1.22 to 1.91). For the three trials with reliable evidence, sensitivity analysis revealed
OR = 1.98 (95% CI 1.16 to 3.38).
Conclusions: Medicines prescribed in individualised homeopathy may have small, specific treatment effects.
Findings are consistent with sub-group data available in a previous ‘global’ systematic review. The low or unclear
overall quality of the evidence prompts caution in interpreting the findings. New high-quality RCT research is
necessary to enable more decisive interpretation.
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The nature of the research evidence in homeopathy is a
matter of ongoing scientific debate. Homeopathy’s advo-
cates tend to deny the worth of randomised controlled
trials (RCTs) [1] or over-interpret their findings, whilst
its critics dispute the therapy’s scientific rationale and
the existence of any positive findings in the research lit-
erature [2]. There is a need to temper these divergent
opinions by considering the existing RCT evidence from
an objective, rigorous and transparent assessment of the* Correspondence: rmathie@britishhomeopathic.org
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methodological quality.
Five systematic reviews have examined the RCT re-
search literature on homeopathy as a whole, including
the broad spectrum of medical conditions that have been
researched and by all forms of homeopathy: four of
these ‘global’ systematic reviews reached the conclusion
that, with important caveats [3], the homeopathic inter-
vention probably differs from placebo [4-7]. By contrast,
the most recent global systematic review, by Shang et al.,
concluded there was “weak evidence for a specific effect
of homeopathic remedies…compatible with the notionThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fects” [8].
Four of the above reviews have distinguished RCTs of
individualised homeopathy, either by mere identification
[4,8] or in formal sub-group analysis [6,7]. In their over-
arching approaches, however, each of these five reviews
has assessed together the RCT findings of all forms of
homeopathy (individualised homeopathy, clinical hom-
eopathy, complex homeopathy, isopathy) as if they are
the same intervention. There are important differences
between these therapeutic approaches, especially that
individualised homeopathy typically involves a long
interview between the practitioner and the patient,
whereas the other three forms (non-individualised
homeopathy) do not. For a placebo-controlled trial of
individualised homeopathy, conclusions about ‘effi-
cacy’ (specific effects) apply potentially to each or just
some of the homeopathic medicines prescribed to the
individual participants in that trial. A meta-analysis of
such RCTs (including those with crossover design,
which we excluded—see ‘Methods’) was published in
1998 [9], using methods that predated the current
rigorous standards for conducting risk-of-bias assess-
ments and sensitivity analysis: it reported a significant
overall treatment effect that marginally was not sus-
tained for the best-quality trials.
We aimed to clarify the results and inferences from
RCTs of individualised homeopathy by conducting an
up-to-date systematic review and meta-analysis to test
the hypothesis: In the context of an RCT, and for the
broad spectrum of medical conditions that have been
researched, the main outcome of an individualised
homeopathic treatment approach using homeopathic
medicines is distinguishable from that of the same
approach using placebos (i.e. individually prescribed
homeopathic medicines have specific effects).
Methods
Methods comply with the PRISMA 2009 Checklist (see
Additional file 1) and with our previously published
protocol [10].
Search strategy, data sources and trial eligibility
A detailed description of the search methods used in this
study has previously been published [11]. We conducted
a systematic literature search to identify RCTs that com-
pared individualised homeopathy with placebos, and for
any medical condition. Each of the following electronic
databases was searched from its inception up to the
end of 2011, with a supplementary search of the same
databases up to the end of 2013: AMED, CAM-Quest®,
CINAHL, Cochrane Central Register of Controlled
Trials, Embase, Hom-Inform, LILACS, PubMed, Science
Citation Index and Scopus. For the 2012/13 update, CORE-Hom® was searched in addition, using the term ‘rando-
mised’, ‘quasi-randomised’ or ‘unknown’ in the ‘Sequence
generation’ field.
The full electronic search strategy for PubMed (Cochrane
Highly Sensitive Search Strategy) is given in our previous
paper [11]: ‘((homeopath* OR homoeopath*) AND ((ran-
domized controlled trial [pt]) OR (controlled clinical trial
[pt]) OR (randomized [tiab]) OR (placebo [tiab]) OR (clin-
ical trials as topic [mesh:noexp]) OR (randomly [tiab]) OR
(trial [ti]))) NOT (animals [mh] NOT humans [mh])’.
As stated in our published protocol [10], we then ex-
cluded trials of crossover design, of radionically prepared
homeopathic medicines, of homeopathic prophylaxis, of
homeopathy combined with other (complementary or
conventional) intervention, or for other specified rea-
sons. The final explicit exclusion criterion was that the
trial’s team members—specifically the homeopathic
practitioner/s—were not blinded to the assigned inter-
vention. All remaining trials were eligible for system-
atic review.
Outcome definitions
We identified one ‘main outcome measure’ from each
study using a refinement of the approaches adopted by
Linde et al. and by Shang et al. [6,8]. Our selection of
each trial’s ‘main outcome measure’ at the study end-
point (i.e. at the end of scheduled follow-up, unless
otherwise indicated) was based on a pre-specified hier-
archical list in order of greatest to least importance, rec-
ommended by the World Health Organization (WHO)
[12]. The WHO approach is an internationally accepted
method to ensure that a selected outcome is the most
vital to the functioning and health of the patient: it thus
ensured our consistent selection of the most important
and objective outcome per trial.
Data extraction
Two reviewers (RTM and either JC, JRTD, LAL or SM)
independently identified the ‘main outcome measure’
and extracted data for each trial using a standard recor-
ding approach [10]. Discrepancies in the identification
and interpretation of data were discussed and resolved
by consensus.
Assessment of risk of bias
We used the domains of assessment as per the Cochrane
risk-of-bias appraisal tool [13]. The extracted informa-
tion enabled appraisal of freedom from risk of bias: ‘Yes’
(low risk), ‘Unclear’ (uncertain risk) or ‘No’ (high risk).
We applied this approach to each of seven domains: se-
quence generation (domain I), allocation concealment
used to implement the random sequence (II), blinding of
participants and study personnel (IIIa), blinding of out-
come assessors (IIIb), incomplete outcome data (IV),
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bias (VI). The source of any research sponsorship (i.e.
potential for vested interest) was taken into account for
sub-group analysis (see below), but not in risk-of-bias
assessment per se.
Reflecting appropriately the designated ‘main outcome
measure’, we rated risk of bias for each trial across all
seven domains and using the following classification [10]:
Rating A = Low risk of bias in all seven domains.
Rating Bx = Uncertain risk of bias in x domains; low
risk of bias in all other domains.
Rating Cy.x = High risk of bias in y domains; uncertain
risk of bias in x domains; low risk of bias in all other
domains.
Designating an RCT as ‘reliable evidence’
An ‘A’-rated trial comprises reliable evidence. We desig-
nated a ‘B1’-rated trial reliable evidence if the uncertainty
in its risk of bias was for one of domains IV, V or VI only
(i.e. it was required to be judged free of bias for each of
domains I, II, IIIa and IIIb).
Statistical analysis
Data
Mean, standard deviation and number of subjects were
extracted for each continuous ‘main outcome’ and the
standardised mean difference (SMD) calculated, reflecting
whether a higher or a lower score was in the direction of
the hypothesis favouring homeopathy; the number of
favourable events and number of subjects were extracted
for each dichotomous ‘main outcome’ and the odds ratio
(OR) calculated. We did not adjust values to compensate
for any inter-group differences at baseline.
For key meta-analyses, a single measure of ‘effect size’
was required to enable pooling of all relevant trials, and
so SMD was transformed to OR using a recognised ap-
proximation method [10]. Random-effects meta-analysis
models were used from the outset due to the known
clinical heterogeneity among studies.
Study selection for meta-analysis
All RCTs that were included in the systematic review were
potentially eligible for meta-analysis. If the original RCT
paper did not provide or inform adequate information on
our selected ‘main outcome’ to enable calculation of the
SMD or the OR, we excluded the trial from meta-analysis
and described the outcome as ‘not estimable’.
Heterogeneity and publication bias
The I2 statistic was used to assess the variability between
studies; this statistic can take values between 0% and
100%, with high values indicative of strong heterogeneity.Funnel plots and Egger’s test were used to assess pub-
lication bias [14,15].
Sensitivity and sub-group analysis
Sensitivity and sub-group analyses were carried out, con-
sistent with our published protocol [10]. The sensitivity
analysis examined the impact on the pooled OR of trials’
risk-of-bias ratings. Included in sub-group analyses, we
aimed to examine whether a trial’s homeopathic medi-
cines had potency ≥12C or <12C (12-time serial dilution
of 1:100 starting solution), a concentration sometimes




The PRISMA flowchart from the original comprehensive
literature search has been published previously [11] and
comprises 489 records. The corresponding flowchart for
RCT records published in 2012/13 is given in Additional
file 2, which features 44 new records. A composite
PRISMA flowchart, in standardised format, is given in
Additional file 3.
Our updated literature search identified a total of five
new records that were potentially eligible for the current
review of RCTs that compared individualised homeop-
athy with placebos (Additional file 4, an update of the
flowchart in our published protocol [10]). All five were
single-blinded and thus ineligible for systematic review.
In total, therefore, 31 records fulfilled the relevant
inclusion criteria. Data were non-extractable from 10
of those (see Additional file 4), leaving 21 records po-
tentially available for meta-analysis. One of the in-
cluded records reported findings from two RCTs. Thus,
the systematic review comprises 32 RCTs, with meta-
analysis of 22 of those RCTs.
Demographic data
The 32 RCTs represented 24 different medical conditions
across 12 categories (Table 1). Homeopathic potency
was ≥12C in 12 trials and was not exclusively ≥12C for
20 trials (mix of >12C and <12C for 12 trials; unstated
for 8 trials). Vested interest was absent in four trials,
uncertain in 18 and present in 10.
Summary of findings
For each trial, Table 2 includes details of the sample size,
the identified ‘main outcome measure’ (and whether
dichotomous or continuous), the end-point and whether
the study was described in the original report as a ‘pilot’
(or ‘preliminary’ or ‘feasibility’) study. The median
sample size (for N = 32 trials) was 43.5 (inter-quartile
range 27 to 67). There were 28 different ‘main outcome
Table 1 Demographic data for 32 randomised controlled trials (RCTs) of individualised homeopathy
# First author Year Category Condition Participants’ demographics Study setting Potency
≥12C/24D
Funding source Free of
vested
interesta
A01 Andrade 1991 Rheumatology Rheumatoid
arthritis
Patients with active RA and




Paulista de Medicina, São
Paulo, Brazil
Mixed None stated U
A05 Bell 2004 Rheumatology Fibromyalgia Fibromyalgia patients Private clinic in the USA Mixed External (government) Y
A06 Bonne 2003 Mental disorder Anxiety Adults aged 18–65 years, of either sex,





Y None stated U
A07 Brien 2011 Rheumatology Rheumatoid
arthritis
Adults formally diagnosed with
RA for at least 2 years, who had
relatively stable disease but some




U National Institute of Health Research;
Samueli Institute, USA; Southampton
Complementary Medicine Research
Trust; Rufford Maurice Laing
Foundation; Dreluso Pharmazeutika
GmBH; National Health Service Fund for
Science
Y
A09 Cavalcanti 2003 Dermatology Uraemic
pruritus
Dialysis for more than 6 months,
moderate to severe pruritus,
absence of other causes for pruritus
Haemodialysis centres, Rio
de Janeiro state, Brazil
Mixed None stated U
A10 Chapman 1999 Neurology Brain injury Patients with mild traumatic brain injury University medical school
in the USA
Y External (government; foundation; hom
pharm providing all meds)
N




URTI Children aged 1.5–10 years, with at least
three upper respiratory tract infections in
the past year or with two such episodes
plus otitis media with effusion at the





Mixed Dutch Ministry of Welfare, Cultural
Affairs, and Public Health
Y
A13 Fisher 2006 Dermatology Eczema Adults aged 18–65 years, of either sex,
with planned treatment for




Mixed None stated U
A14 Frass 2005 Surgery and
anaesthesiology
Sepsis Patients with severe sepsis Intensive Care Unit at a
university hospital in
Austria
Y None stated U
A16 Gaucher 1994 Tropical disease Cholera Patients with cholera, in a
state of dehydration requiring
parenteral treatment
University of San Marcos,
Lima, Peru
U None stated; several acknowledged,
including employee of hom pharm
company
U
A18 Jacobs 1993 Gastroenterology Childhood
diarrhoea
Children aged 0.5–5 years, with
history of acute diarrhoea
Participants’ homes, Leon,
Nicaragua
Y Boiron Research Foundation, Norwood,
Pennsylvania, USA,
U
A19 Jacobs 1994 Gastroenterology Childhood
diarrhoea
Children with a history of acute diarrhoea Nicaragua Y External, including hom pharm that
might have provided the remedies for
the trial
U


























Table 1 Demographic data for 32 randomised controlled trials (RCTs) of individualised homeopathy (Continued)
A21 Jacobs 2000 Gastroenterology Childhood
diarrhoea
Children with a history
of acute diarrhoea
Nepal Y External (hom research foundation) U





Women with history of carcinoma or
stage I–III breast cancer who had
completed all surgery, chemotherapy and
radiation treatment and who averaged at




U External (charity); meds donated by
hom pharm
N
A23 Jacobs 2005a Mental disorder ADHD Children, aged 6–12 years, meeting
DSM-IV criteria for ADHD
Private homeopathic clinic
in Seattle, USA
U External (government); meds donated
by hom pharm
N





Y None stated U
A25 Kainz 1996 Dermatology Warts Children aged 6–12 years, with common




Mixed Firma Spagyra, Groding, Austria: ‘kindly
provided’ homeopathic medicines and
placebos. Otherwise, none stated
N
A26 Katz 2005 Mental disorder Depression Adults, aged 18–80 years, of either sex,
suffering from major depressive episode
of moderate severity as defined by DSM-IV
Lower Clapton group
practice, east London, UK
U Homeopathic Research Committee;
Blackie Foundation Trust. Verum and
placebo homeopathic medicines
donated by Laboratoires Boiron
N
A30 Naudé 2010 Mental disorder Insomnia Insomnia sufferers (identified through
local advertising)
South Africa Mixed None stated U
A31 Rastogi (a) 1999 Immune
disorder
HIV Adults aged 18–50 years, of either sex,
with positive antibody reaction to HIV-1 or





Mixed None stated U
A31 Rastogi (b) 1999 Immune
disorder
HIV Adults aged 18–50 years, of either sex,
with positive antibody reaction to HIV-1 or





Mixed None stated U
A32 Sajedi 2008 Neurology Cerebral
palsy
Children aged 1–5 years, with mild to





A33 Siebenwirth 2009 Dermatology Eczema Adults aged 18–35 years with at
least a 1-year history of atopic
dermatitis (>20% of skin surface)





Mixed The study medications gifted by
Deutsche Homöopathie-Union (DHU).
Funded by Karl und Veronica Carstens-
Stiftung
N
A34 Steinsbekk 2005 Respiratory
infection
URTI Children, under 10 years old, who had
been to a medical doctor for URTI




when attending a hospital
casualty department
Y External: Norwegian Research Council.






















Table 1 Demographic data for 32 randomised controlled trials (RCTs) of individualised homeopathy (Continued)
A35 Straumsheim 2000 Neurology Migraine Adults aged 18–65 years, of either sex,
diagnosed according to International
Headache Society classification criteria
Arena Medisinske Senter,
Oslo, Norway
Mixed DCG Farmaceutia (Gotenborg): supplied
all homeopathic medicines. Norwegian
Research Council
N





Women who attended oncology
centre for breast cancer, did not have
metastatic disease, were not on any
other treatment and experiencing




Y External (charity; hom pharm
—‘provided’ all remedies, presumably
via hospital pharmacy dept)
U
A37 Walach 1997 Neurology Headache Patients diagnosed according to
the International Headache
Society classification criteria






2004 Mental disorder Chronic
fatigue
syndrome
Adults with chronic fatigue Two outpatient
departments in UK
U External (charity) Y




Children, aged 5–15 years, with diagnosis
of asthma and prescription for beta
agonist and/or corticosteroid inhaler
issued within previous 3 months
Five general practices in
market towns in Somerset,
UK
U External, including hom pharm that
provided all remedies
N
A40 Whitmarsh 1997 Neurology Migraine Adults aged 18–60 years, of either sex,





Y Nelsons Ltd; Homeopathic Medical
Research Council; Blackie Foundation
Trust
U




Women aged 20–50 years, with diagnosis
of PMS according to pre-defined criteria;





Y Dolisos Laboratories; Deutsche
Homeopathie Union; named individuals
N
The complete bibliographic details for the studies included are found in Additional file 4. Y yes, U unclear, N no, RA rheumatoid arthritis, URTI upper respiratory tract infection. aVested interest: support (direct, through




















Table 2 Summary of findings table








‘Main’ outcome identified Nature of ‘main’
outcome
End-point
A01 Andrade 1991 N 44 33 N 25.0 Ritchie articular index Continuous 6 months
A05 Bell 2004 Y 62 53 Y 14.5 Tender point pain on palpation Continuous 3 months
A06 Bonne 2003 N 44 39 N 11.4 Hamilton Rating Scale for Anxiety (HAM-A) Continuous 10 weeks
A07 Brien 2011 N 32 23 N 28.1 Proportion of patients meeting ACR 20%
improvement criteria (‘ACR20 response’)
Dichotomous 28 weeks
A09 Cavalcanti 2003 N 28 20 N 28.6 Responders: patients with more than 50%
reduction in pruritus score
Dichotomous 60 days
A10 Chapman 1999 Y 61 50 Y 18.0 SRH-SLPD functional assessment tool:
SRS (symptoms) sub-scale
Continuous 4 months
A11 de Lange de
Klerk
1994 N 175 170 Y 2.9 Daily total symptom score Continuous 1 year
A13 Fisher 2006 Y 38 27 N 28.9 VAS of overall symptom severity Continuous 13 weeks
A14 Frass 2005 N 70 67 Y 4.3 Patient survival Dichotomous 180 days
A16 Gaucher 1994 N 80 51 Y 36.3 Degree of dehydration Continuous 12 h
A18 Jacobs 1993 N 34 33 N 2.9 Number of days until fewer than 3 unformed
stools for 2 consecutive days
Continuous Up to 6 days
A19 Jacobs 1994 N 92 81 Y 12.0 Number of days until fewer than 3 unformed
stools for 2 consecutive days
Continuous Up to 5 days
A20 Jacobs 2001 Y 75 75 Y 0.0 Treatment failure Dichotomous 5 days (cumulative total)
A21 Jacobs 2000 N 126 116 Y 7.9 Number of days until fewer than 3 unformed
stools for 2 consecutive days
Continuous 5 days
A22 Jacobs 2005b Y 53 33 N 37.7 Hot flash severity score Continuous 12 months
A23 Jacobs 2005a Y 43 37 N 14.0 Conners Global Index–Parent (CGI-P)—total Continuous 17 weeks
A24 Jansen 1992 Y 10 4 N 60.0 Endoscopic appearance (grade) Continuous 12 months
A25 Kainz 1996 N 67 60 Y 10.4 Responders: patients with at least 50%
reduction in area of skin affected by warts
Dichotomous 8 weeks
A26 Katz 2005 Y 7 3 N 57.1 Hamilton Depression Scale (HAMD) Continuous 12 weeks
A30 Naudé 2010 N 33 30 N 9.1 Sleep Impairment Index (SII) summary score Continuous 4 weeks
A31 Rastogi (a) 1999 N 50 42 N 16.0 CD4+ T-lymphocyte counts Continuous 6 months
A31 Rastogi (b) 1999 N 50 38 N 24.0 CD4+ T-lymphocyte counts Continuous 6 months
A32 Sajedi 2008 N 24 16 N 33.3 Modified Ashworth Scale: measurement of
muscle tone in right leg
Continuous 4 months
A33 Siebenwirth 2009 N 24 14 N 41.7 MP (multiparameter dermatitis) score Continuous 32 weeks
A34 Steinsbekk 2005 N 251 199 Y 20.7 Parent-reported URTI total symptom score Continuous Duration of 12 weeks





















Table 2 Summary of findings table (Continued)
A36 Thompson 2005 Y 53 45 Y 15.1 MYMOP profile score Continuous 16 weeks
A37 Walach 1997 N 98 92 Y 6.1 Frequency of headaches per month Continuous Last month of 3-month
period
A38 Weatherley-Jones 2004 N 103 86 Y 16.5 Responders: those with clinical
improvement (Multidimensional
Fatigue Inventory: mental fatigue)
Dichotomous 7 months
A39 White 2003 N 89 74 Y 16.9 Childhood Asthma Questionnaire (CAQ)
sub-scale for severity of symptoms
Continuous 52 weeks
A40 Whitmarsh 1997 N 63 60 Y 4.8 Frequency of migraine attacks per month Continuous Last month of 4-month
period
A41 Yakir 2001 Y 23 19 N 17.4 Menstrual distress questionnaire (MDQ) score Continuous Duration of 3 months
(last 7 days per cycle)
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12 months.
Risk of bias and reliable evidence
Table 3 provides the risk-of-bias details for each of the
32 trials and sub-divided by (a) included in our meta-Table 3 Risk-of-bias assessments for trials: (a) included in me
# First author Year Risk-o
I II IIIa
(a): Included in meta-analysis
A11 de Lange de Klerk 1994 U U U
A19 Jacobs 1994 Y Y Y
A25 Kainz 1996 U U U
A10 Chapman 1999 Y U Y
A35 Straumsheim 2000 U U Y
A20 Jacobs 2001 Y Y Y
A41 Yakir 2001 U U Y
A06 Bonne 2003 U U Y
A05 Bell 2004 Y Y Y
A14 Frass 2005 Y U Y
A23 Jacobs 2005a Y U Y
A36 Thompson 2005 Y U Y
A40 Whitmarsh 1997 U U Y
A31 Rastogi (a) 1999 U U U
A31 Rastogi (b) 1999 U U U
A09 Cavalcanti 2003 U U Y
A38 Weatherley-Jones 2004 Y U Y
A22 Jacobs 2005b Y Y Y
A13 Fisher 2006 Y U Y
A32 Sajedi 2008 U U U
A33 Siebenwirth 2009 U Y Y
A07 Brien 2011 Y Y Y
(b): Not included in meta-analysis
A01 Andrade 1991 U U U
A24 Jansen 1992 U U U
A18 Jacobs 1993 U U Y
A16 Gaucher 1994 N N U
A37 Walach 1997 U Y Y
A21 Jacobs 2000 Y Y Y
A39 White 2003 Y Y Y
A26 Katz 2005 Y U Y
A34 Steinsbekk 2005 Y Y Y
A30 Naudé 2010 Y U Y
Trials are arranged chronologically within their risk-of-bias rating category.
aUnless a published study protocol was available, completeness of reporting (doma
section of paper.
bReliable evidence.
Y yes, U unclear, N no (regarding freedom from risk of bias).analysis and (b) not included in our meta-analysis. Do-
main IIIa (blinding of participants and trial personnel)
contributed the least risk of bias overall, with no trial
classed ‘high risk’. Domain IV (completeness of outcome
data) presented the greatest methodological concerns,
with 14 trials judged ‘high risk’. Domain II (allocationta-analysis and (b) not included in meta-analysis
f-bias domain Risk of
bias
Risk-of-
bias ratingIIIb IV Va VI
U Y Y Y Uncertain B4
Y U Y Y Uncertainb B1
U U Y U Uncertain B6
Y Y Y Y Uncertain B1
Y Y Y Y Uncertain B2
Y U Y Y Uncertainb B1
Y U Y Y Uncertain B3
Y Y Y U Uncertain B3
Y Y Y U Uncertainb B1
U Y Y Y Uncertain B2
Y Y Y Y Uncertain B1
Y Y Y Y Uncertain B1
U Y U N High C1.4
U N N U High C2.5
U N N U High C2.5
Y N Y U High C1.3
Y N Y Y High C1.1
Y N Y Y High C1.0
Y N Y U High C1.2
U N Y Y High C1.4
Y N Y N High C2.1
Y N Y Y High C1.0
U N N U High C2.5
U N N N High C3.4
Y U N U High C1.4
U N N U High C4.3
U Y N N High C2.2
Y Y N N High C2.0
Y Y N Y High C1.0
U N N N High C3.2
Y N N Y High C2.0
Y U N Y High C1.2
in V) was judged solely on correspondence of ‘Results’ with details in ‘Methods’
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logical judgments, with 21 (66%) trials assessed ‘unclear
risk’ and 10 (31%) assessed ‘low risk’. A risk-of-bias bar
graph is shown in Additional file 5.
Table 3(a): No trial was ‘A’-rated (low risk of bias over-
all)—i.e. none fulfilled the criteria for all seven domains
of assessment. Table 3(a) therefore includes a list of 12
trials that were classed uncertain risk of bias (‘B’-rated)
and 10 that were classed high risk of bias (‘C’-rated).
Table 3(a) also shows the three ‘B1’-rated trials that sat-
isfied our criteria for reliable evidence. All other trials
had unclear or high risk of bias in important methodo-
logical aspects and may be regarded as non-reliable
evidence.
Table 3(b): Trials that were deficient in domain V (se-
lective outcome reporting) included the ten whose data
were not extractable for meta-analysis and which were
thus ‘C’-rated by default; seven of these ten trials wereStudy






























Figure 1 Forest plot showing odds ratio (OR) and 95% confidence int
pooled OR (random-effects [RE] model) for trials with continuous outalready ‘C’-rated due to deficiency in at least one other
domain of assessment.
Meta-analysis
The data extracted per trial (continuous or dichotomous
data) are tabulated in Additional file 6. Figure 1 illus-
trates the OR for each trial; the original SMD data for
each of the studies with continuous data are shown in
Additional file 7. Of the 22 trials, 15 had an effect
favouring homeopathy (i.e. OR > 1), 3 of them statisti-
cally significantly; 7 trials had an effect favouring pla-
cebo, none of them significantly. Total sample size =
1,123 (N = 22 trials).
Pooled OR was 1.53 (95% confidence interval (CI) 1.22
to 1.91; P < 0.001). There was no difference depending
on whether the ‘main outcome’ was continuous (OR =
1.45; 95% CI 1.12 to 1.89) or dichotomous (OR = 1.80




























 [1.22;  1.91]
 [1.12;  1.89]
 [1.12;  2.87]
 [0.96;  2.89]
 [1.00;  4.94]
 [0.69;  4.34]
 [0.72;  5.49]
 [0.45;  4.10]
 [0.17;  1.69]
 [0.34;  1.90]
 [0.96; 31.62]
 [0.28;  2.73]
 [0.66;  4.72]
 [0.25;  2.57]
 [1.06; 13.90]
 [0.66;  5.64]
 [0.34;  5.30]
 [0.09;  3.34]
 [0.07;  3.65]
 [0.45;  4.45]
 [0.63;  5.36]
 [0.55; 22.30]
 [0.62;  3.47]
 [1.10;  8.86]
 [0.16;  4.47]
Favours homeopathy
erval (CI) for each of 22 RCTs of individualised homeopathy, with
comes, dichotomous outcomes, and for all 22 RCTs.
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Despite the clinical heterogeneity across the studies, the
statistical heterogeneity between the studies was low (I2 =
0% [95% CI 0% to 40%]), and therefore the variability in
the estimated pooled OR is also relatively low. No evi-
dence of publication bias was apparent from the funnel
plot (Figure 2) or from Egger’s test (P = 0.59).
Risk of bias and reliable evidence
Figure 3a shows the OR data for all 22 trials, grouped by
their ‘B’- or ‘C’-rating. There was no difference between
‘B’- and ‘C’-rated trials: P = 0.41.
 ‘Uncertain risk of bias’ (all ‘B’-rated; N = 12):
OR = 1.63 (95% CI 1.24 to 2.14; P < 0.001);
 ‘High risk of bias’ (all ‘C’-rated; N = 10): OR = 1.33
(95% CI 0.90 to 1.98; P = 0.15).
Figure 3b shows the OR data for the 12 ‘B’-rated trials,
grouped by reliability of evidence. There was no differ-
ence between the two sub-sets (P = 0.42).
 Uncertain risk of bias/reliable evidence (N = 3):
OR = 1.98 (95% CI 1.16 to 3.38; P = 0.013).Figure 2 Funnel plot: 22 RCTs of individualised homeopathy. Uncertain risk of bias/non-reliable evidence (N = 9):
OR = 1.53 (95% CI 1.09 to 2.14; P = 0.014).
Sensitivity analysis
Figure 4 shows the effect of removing data by trials’
risk-of-bias rating; full details are given in Additional
file 8. The set of six trials rated ‘B1’ has been sub-
divided by those with/without reliable evidence. The
pooled OR showed a statistically significant effect
in favour of homeopathy for every value of N, down to
and including the final N = 3 trials with reliable
evidence. Additional file 8 also states whether a trial
was included in the ‘global’ analyses by Linde and/or
Shang [6,8]: of the 22 RCTs we subjected to meta-
analysis, 8 had previously been analysed and 14 had
not (our selected ‘main outcome measure’ differs for
3 of the 8 trials also included by Shang—Additional
file 9).
Sub-group analyses
Pooled OR favoured homeopathy for all sub-groups
and was statistically significant for all but two of them
(<median; potency not exclusively ≥12C): Figure 5a.
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Figure 3 Forest plots showing odds ratio (OR) and 95%
confidence interval (CI) for each of (a) 22 RCTs of
individualised homeopathy, with pooled OR (random-effects
[RE] model) for trials with unclear risk of bias (RoB),
high RoB, and for all 22 RCTs; (b) 12 ‘B’-rated RCTs of
individualised homeopathy, with pooled OR (RE model) for
trials with non-reliable evidence, reliable evidence, and for
all 12 RCTs.
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http://www.systematicreviewsjournal.com/content/3/1/142statistic between any sub-groups. Similar results were
seen for the N = 12 (Figure 5b) and N = 3 analyses (data
not illustrated). Full details are given in Additional
file 10. We observed a statistically significant pooled
OR, favouring homeopathy, for the eight trials that
we have in common with those previously reported by
Shang et al. [8].Discussion
Twenty-nine of the 32 trials had unclear or high risk
of bias in important domains of assessment. Poor
reporting or other deficiencies in the original papers
prevented data extraction for meta-analysis from 10
of the 32 trials; the potential influence of the 10 on
our overall meta-analysis is unknown, but because of
their intrinsic low quality, their absence does not alter
our principal conclusions. High and unclear risk of
bias featured almost equally in our 22-trial analysis;
thus, the overall quality of analysed evidence was low
or unclear, necessitating caution in interpreting the
findings.
As was the case for the previous ‘global’ systematic
reviews of homeopathy RCTs that have included meta-
analysis [6,8], there are obvious limitations in pooling
data from diverse medical conditions, outcome mea-
sures and end-points. Thus, a given pooled effects esti-
mate here does not have a clear numerical meaning
or relative clinical value: it is a summary measure that
enables statistical significance and mean ‘effect size’
to be attributed and to be interpreted in testing an
hypothesis that individually prescribed homeopathic
medicines have specific effects.
Though our conclusions can be made most securely
from three trials with reliable evidence, this sub-set of
studies is too small to enable a decisive answer to our
tested hypothesis. Equivocal RCT evidence of this
nature is not unusual in medical science, in which
conclusions are commonly based on just two eligible
RCTs per systematic review [17]. Given the specific
focus of our study, a statistically significant OR of 1.98
may be interpreted as a small ‘effect size’ for these
three trials collectively and does not differ significantly
from the ‘effect size’ observed in our analysis of 22 tri-
als (OR = 1.53). Such ‘effect sizes’ seem comparable
with, for example, sumatriptan for migraine, fluoxetine
for major depressive disorder and cholinesterase inhib-
itors for dementia [18]. The detection of a small yet
significant pooled OR, with the perspective that only a
few single trials showed statistically significant effects,
supports conjecture that the impact of an indivi-
dualised homeopathic prescription may be difficult to
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Figure 4 Sensitivity analysis, showing progressive effect on pooled odds ratio (OR) of removing data by trials’ risk-of-bias rating.
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and internally consistent, and the methodological im-
plications of our risk-of-bias findings are the same as
those for RCTs in conventional medicine. Indeed, it is
noteworthy that domain II (allocation concealment)
had the fewest ‘low risk of bias’ assessments (for 31%
of our trials): this compares historically with adequately
described allocation concealment in just 16% conventional
medicine trials that were published during the period
1960 to 1995 [21].
Two of the three trials with reliable evidence used med-
icines that were diluted beyond the Avogadro limit. Our
pooled effects estimate for the three trials, therefore, is
either a false positive or it reflects the relevance of new
hypotheses about the biological mechanism of action of
homeopathic dilutions [22,23]. It should also be noted
that one of these same three trials displayed evidence of
vested interest. It remains to be seen if our assessments
of model validity [24] support or refute the legitimacy
of these three trials as currently the most important
contributors to the evidence base in individualised
homeopathy.
Comparison with previous systematic reviews
Our database is different from that of both Linde and
Shang [6,8]. Firstly, we concentrated solely on peer-
reviewed trials of individualised homeopathic treat-
ment. Secondly, we have an updated set of trials for
meta-analysis: 14 of our 22 RCTs were not included in
the previous ‘global’ analyses. Thirdly, our selected
‘main outcome measure’—and thus our calculated
OR—differs for three of the eight previously analysedtrials of individualised homeopathy. Fourthly, our
group of three RCTs with ‘reliable evidence’ is
founded on a more exacting standard than for Shang’s
‘trials of higher methodological quality’: indeed, by
Shang’s explicit criteria for domains IV, V and VI, we
would label five of our ‘non-reliable’ trials [20,25-28]
as ‘higher methodological quality’.
A notable finding from sub-group analysis is that
our 14 newly examined trials do not differ in ‘effect
size’ from the eight that were included in previous
‘global’ meta-analysis by Shang et al. [8], disputing
suggestions that the evidence base in homeopathy is
weakening with time [29]. Noteworthy too is the sig-
nificantly positive pooled OR that we observed for
those eight trials and the close similarity of its value to
that calculable from Shang’s forest plot data for the
same eight [30].
Like us, Linde and colleagues reported a pooled OR
of 1.50–2.00 for the highest-quality RCTs [3,6]. In
their separate analysis of individualised homeopathy,
however, Linde and Melchart noted a smaller ‘effect
size’ whose statistical significance was only marginally
not sustained for the highest-quality trials [9]. Unlike
our predecessors, we found no evidence that lower-
quality trials displayed a larger treatment effect than
that of higher-quality studies: indeed, our ten ‘C’-
rated trials with extractable data displayed a non-
significant pooled effects estimate. It may be that our
stringent judgmental approach led to a less extreme
range of quality assessments than those of the earlier
reviewers. Importantly, we found no evidence of pub-
lication bias, removing any need for data adjustment.
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Figure 5 Interactions between sub-groups for (a) all N = 22 trials with analysable data and (b) N = 12 ‘B’-rated trials.
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 There was a small, statistically significant, treatment
effect of individualised homeopathic treatment that
was robust to sensitivity analysis based on ‘reliable
evidence’.
 Findings are consistent with sub-group data
available in a previous ‘global’ systematic review
of homeopathy RCTs.
 The overall quality of the evidence was low or
unclear, preventing decisive conclusions.
 New RCT research of high quality on
individualised homeopathy is required to enhancethe totality of reliable evidence and thus enable
clearer interpretation and a more informed
scientific debate.Additional files
Additional file 1: Checklist. PRISMA 2009 Checklist.
Additional file 2: PRISMA flowchart for records published in 2012
or 2013.
Additional file 3: PRISMA flowchart for all records published up to
and including 2013.
Additional file 4: Details of records of RCTs of individualised
homeopathy. Asterisk: paper reports two RCTs. Double asterisk: trial
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inspection of published protocol. SD standard deviation. Reference
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Additional file 5: Risk-of-bias bar-graph for 32 RCTs of individualised
homeopathy.
Additional file 6: Data extracted for meta-analysis of RCTs with: (a)
continuous main outcome measure and (b) dichotomous main
outcome measure.
Additional file 7: Standardised mean difference (SMD) and 95%
confidence interval (CI) for RCTs with continuous main outcome
measure, showing pooled statistic (random effects [RE] model).
Additional file 8: Sensitivity analysis on risk-of-bias rating, and
including specified demographic data per trial.
Additional file 9: Meta-analysed trials in common with those
included by Shang et al. [8], showing comparison of quality
assessment and degree of similarity of selected outcome measure.
Additional file 10: Sub-group analysis showing interaction for: (a)
all N = 22 trials with analysable data, (b) N = 12 (‘B’-rated) trials with
uncertain risk of bias and (c) sub-set of (‘B1’-rated) trials with
reliable evidence.
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